Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Shore on the FDA Approval of Relugolix in Advanced Prostate Cancer

December 18th 2020

Neal D. Shore, MD, FACS, discusses the approval of relugolix in advanced prostate cancer.

FDA Approves Relugolix for Advanced Prostate Cancer

December 18th 2020

December 18, 2020 - The FDA has approved the oral gonadotropin-releasing hormone receptor antagonist relugolix as a treatment for patients with advanced prostate cancer.

AR Inhibitors Lead to Higher Fall/Fracture Risk in Older Men With Prostate Cancer

December 17th 2020

December 17, 2020 - Androgen receptor inhibitor–therapy is associated with an increased risk of falls and fractures in patients with prostate cancer. However, since it has shown improvement in overall survival, the benefits may outweigh the risk.

Dr. Hurwitz Compares the Utility of Antiandrogens in Nonmetastatic CRPC

December 16th 2020

Michael E. Hurwitz, MD, PhD, compares the utility of antiandrogens in nonmetastatic castration-resistant prostate cancer.

Sequence of ADT With Radiation Is Crucial for Prostate Cancer Treatment

December 15th 2020

December 15, 2020 — The sequence in which hormonal therapy is given to men with localized prostate cancer should be considered as it can significantly affect outcomes.

Dr. Agarwal on Remaining Challenges in mCSPC

December 11th 2020

Neeraj Agarwal, MD, remaining challenges in metastatic castration-sensitive prostate cancer.

Gene Expression Testing Varies Substantially by Region for Prostate Cancer

December 10th 2020

December 10, 2020 — Despite gene expression tests helping health care professionals make optimal treatment decisions, testing varies by region for men with prostate cancer and could be related to socioeconomic status and patterns of prostate cancer care.

Standardized Practices Address Challenges With Germline Genetic Testing in Prostate Cancer

December 8th 2020

December 8, 2020 — Although updated guidelines and targeted therapies have led to the routine recommendation of germline genetic testing for patients with prostate cancer, increasing demand for tests and limited access to genetics providers have created an unmet need.

Dr. Schweizer on the Role of Olaparib in Non–BRCA-Mutant mCRPC

December 7th 2020

Michael Schweizer, MD, discusses the role of olaparib in patients with non–BRCA-mutant metastatic castration-resistant prostate cancer.

Oxidative Stress, Antioxidant Status Remain High in Nigerian Patients With Prostate Cancer

December 4th 2020

Nigerian patients with prostate cancer are noted as having higher levels of total plasma peroxide, malondialdehyde, and nitric oxide, as well as lower levels of total antioxidant capacity, even while undergoing androgen-deprivation therapy compared with Nigerian men who don't have prostate cancer.

Dr. Petrylak on the Role of Docetaxel in mHSPC

December 2nd 2020

Daniel P. Petrylak, MD, discusses the role of docetaxel based on the results of the ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Dr. Agarwal on Unmet Needs in mHSPC

December 1st 2020

Neeraj Agarwal, MD, discusses unmet needs in metastatic hormone-sensitive prostate cancer.

FDA Approves Gallium 68 PSMA-11 as PET-Imaging Drug for Prostate Cancer

December 1st 2020

December 1, 2020 - The FDA has approved Gallium 68 PSMA-11, the first drug for PET imaging of prostate-specific membrane antigen–positive lesions in patients with prostate cancer.

Novel Tubulin-Targeting Therapies Make Headway

November 30th 2020

Clinical findings have recently been reported for 2 of the more advanced emerging tubulin-targeting agents, VERU-111 and plinabulin.

Dr. Choyke on Recent Developments in Imaging for Prostate Cancer

November 25th 2020

Peter L. Choyke, MD, FACR, discusses recent developments in imaging for prostate cancer.

Dr. Boutros on the Utility of Genetic Testing in Prostate Cancer

November 24th 2020

Paul C. Boutros, PhD, MBA, discusses the utility of genetic testing in prostate cancer.

Dr. Lin on the Limitations of Current Biomarkers in Prostate Cancer

November 23rd 2020

Daniel W. Lin, MD, discusses the limitations of currently available biomarkers in prostate cancer.

T-cell Signatures Suggest Existence of Immune-Responsive Microsatellite-Stable mCRPC

November 23rd 2020

November 23, 2020 - Patients with microsatellite instable metastatic castration-resistant prostate cancer have a distinct T-cell signature that is detectable in the peripheral blood.

Dr. Lin on the Importance of Biomarker Research in Prostate Cancer

November 19th 2020

Daniel W. Lin, MD, discusses the importance of biomarker research in prostate cancer.

Dr. Greene on the Future of Personalized Therapy in Prostate Cancer

November 19th 2020

Kirsten ​L. Greene, MD, MAS, FACS, discusse​s the future of personalized therapy in prostate cancer.

NEXT PAGE
PREVIOUS PAGE